We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) closed at $18.76, marking a +0.59% move from the previous day. This move lagged the S&P 500's daily gain of 0.76%. Elsewhere, the Dow gained 0.67%, while the tech-heavy Nasdaq added 0.71%.
Heading into today, shares of the company had gained 14.49% over the past month, outpacing the Medical sector's loss of 1.02% and the S&P 500's gain of 0.75% in that time.
Investors will be hoping for strength from TEVA as it approaches its next earnings release, which is expected to be February 13, 2019. In that report, analysts expect TEVA to post earnings of $0.55 per share. This would mark a year-over-year decline of 40.86%. Meanwhile, our latest consensus estimate is calling for revenue of $4.53 billion, down 17.01% from the prior-year quarter.
Investors might also notice recent changes to analyst estimates for TEVA. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. TEVA currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that TEVA has a Forward P/E ratio of 6.65 right now. For comparison, its industry has an average Forward P/E of 9.51, which means TEVA is trading at a discount to the group.
Meanwhile, TEVA's PEG ratio is currently 5.66. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Generic Drugs industry currently had an average PEG ratio of 1.15 as of yesterday's close.
The Medical - Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 68, putting it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) closed at $18.76, marking a +0.59% move from the previous day. This move lagged the S&P 500's daily gain of 0.76%. Elsewhere, the Dow gained 0.67%, while the tech-heavy Nasdaq added 0.71%.
Heading into today, shares of the company had gained 14.49% over the past month, outpacing the Medical sector's loss of 1.02% and the S&P 500's gain of 0.75% in that time.
Investors will be hoping for strength from TEVA as it approaches its next earnings release, which is expected to be February 13, 2019. In that report, analysts expect TEVA to post earnings of $0.55 per share. This would mark a year-over-year decline of 40.86%. Meanwhile, our latest consensus estimate is calling for revenue of $4.53 billion, down 17.01% from the prior-year quarter.
Investors might also notice recent changes to analyst estimates for TEVA. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. TEVA currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that TEVA has a Forward P/E ratio of 6.65 right now. For comparison, its industry has an average Forward P/E of 9.51, which means TEVA is trading at a discount to the group.
Meanwhile, TEVA's PEG ratio is currently 5.66. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Generic Drugs industry currently had an average PEG ratio of 1.15 as of yesterday's close.
The Medical - Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 68, putting it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.